Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 4,833
- 主要终点
- Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment
研究概览
简要总结
This is a multicenter, randomized, open-label, assessor-blind, event-driven, non-inferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic pulmonary embolism (PE) with or without symptomatic Deep-Vein Thrombosis (DVT) (Einstein-PE).
详细描述
Within the US 'Johnson & Johnson Pharmaceutical Research & Development, L.L.C.' is sponsor.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed acute symptomatic proximal PE with or without symptomatic DVT
排除标准
- •Legal lower age limitations (country specific)
- •Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current episode of DVT and/or PE
- •Other indication for VKA than DVT and/or PE
- •The pre-randomization anti-coagulant treatment (Criteria # 4) has been prolonged from 36 hours to a maximum of 48 hours.
研究组 & 干预措施
Rivaroxaban (Xarelto, BAY59-7939)
Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)
干预措施: Rivaroxaban (Xarelto, BAY59-7939) (Drug)
Enoxaparin/VKA
Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 - 3.0)
干预措施: Enoxaparin overlapping with and followed by VKA (Drug)
结局指标
主要结局
Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment
时间窗: 3-, 6-, or 12-month study treatment period
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries.
次要结局
- Percentage of Participants With the Composite Variable Comprising Recurrent DVT, Non-fatal PE and All Cause Mortality Until the Intended End of Study Treatment(3-, 6-, or 12-month study treatment period)
- Percentage of Participants With an Event for Net Clinical Benefit 1 Until the Intended End of Study Treatment(3-, 6-, or 12-month study treatment period)
- Percentage of Participants With Recurrent PE Until the Intended End of Study Treatment(3-, 6- or 12-month study treatment period)
- Percentage of Participants With Recurrent DVT Until the Intended End of Study Treatment(3-, 6- or 12-month study treatment period)
- Percentage of Participants With Clinically Relevant Bleeding, Treatment-emergent (Time Window: Until 2 Days After Last Dose)(3-, 6- or 12-month study treatment period)
- Percentage of Participants With All Deaths(3-, 6- or 12-month study treatment period)
- Percentage of Participants With Other Vascular Events, On-treatment (Time Window: Until 1 Day After Last Dose)(3-, 6- or 12-month study treatment period)